Renascience Inc. Logo

Renascience Inc.

Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.

4889 | T

Overview

Corporate Details

ISIN(s):
JP3981100005
LEI:
Country:
Japan
Address:
仙台市青葉区星陵町2−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Renascience Inc. is a research and development company engaged in the development and commercialization of pharmaceuticals and medical devices. The company focuses on creating innovative treatments derived from basic research to address various medical issues, including diseases associated with aging and hereditary conditions. Its R&D pipeline includes new drug candidates, such as antisense oligonucleotides, and advanced medical technology, such as a programmed medical device that utilizes artificial intelligence (AI) to support hemodialysis. Renascience actively forms strategic collaborations with pharmaceutical partners and academic institutions to advance its development projects and bring novel therapies to market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 07:39
Report Publication Announcement
確認書
Japanese 8.7 KB
2025-11-12 07:37
Interim Report
半期報告書-第27期(2025/04/01-2026/03/31)
Japanese 434.5 KB
2025-09-03 08:37
Regulatory News Service
確認書
Japanese 8.7 KB
2025-09-03 08:30
Regulatory News Service
訂正有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 1.7 MB
2025-06-27 08:35
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2025-06-24 08:36
Governance Information
内部統制報告書-第26期(2024/04/01-2025/03/31)
Japanese 23.2 KB
2025-06-24 08:35
Registration Form
確認書
Japanese 8.7 KB
2025-06-24 08:33
Registration Form
有価証券報告書-第26期(2024/04/01-2025/03/31)
Japanese 3.5 MB
2024-11-14 07:37
Interim Report
確認書
Japanese 8.7 KB
2024-11-14 07:36
Interim Report
半期報告書-第26期(2024/04/01-2025/03/31)
Japanese 288.9 KB
2024-06-28 04:56
Post-Annual General Meeting Information
臨時報告書
Japanese 24.5 KB
2024-06-28 04:32
Governance Information
内部統制報告書-第25期(2023/04/01-2024/03/31)
Japanese 22.7 KB
2024-06-28 04:26
Registration Form
確認書
Japanese 8.7 KB
2024-06-28 04:24
Annual Report
有価証券報告書-第25期(2023/04/01-2024/03/31)
Japanese 3.5 MB
2024-05-27 10:10
Board/Management Information
臨時報告書
Japanese 22.4 KB

Automate Your Workflow. Get a real-time feed of all Renascience Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Renascience Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Renascience Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

VALIRX PLC Logo
Advancing oncology & women's health therapeutics and offering preclinical research services.
United Kingdom
VAL
VALUE GOLF Inc. Logo
A golf services hub offering reservations, solo player bookings, e-commerce, lessons, and tours.
Japan
3931
Value HR Co., Ltd. Logo
Offers a health management platform and consulting for corporate health insurance societies in Japan.
Japan
6078
Global OTA for curated tours & experiences, focusing on travel to and from Japan.
Japan
7048
A South Korean travel company offering global tour packages, flights, hotels, and corporate travel.
South Korea
094850
Virax Biolabs Group Ltd Logo
Specializes in T-cell immunity tests and diagnostics for profiling viral disease responses.
United States of America
VRAX
VisionSys AI Inc Logo
Develops AI-powered brain-computer interfaces for the healthcare and biotech sectors.
United States of America
VSA
Vivesto Logo
Develops and licenses novel cancer therapies for humans and animals using proprietary drug delivery.
Sweden
VIVE
Vor Biopharma Inc. Logo
Clinical-stage biotech developing next-gen medicines that target the root cause of autoimmune disease.
United States of America
VOR
Voronoi, Inc. Logo
Develops selective kinase inhibitors and targeted protein degraders for precision oncology.
South Korea
310210

Talk to a Data Expert

Have a question? We'll get back to you promptly.